$STOK News

JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net Proceeds

Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M Estimate

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44